LSM-775, also known as N-morpholinyllysergamide or as lysergic acid morpholide, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD).
Use and effects LSM-775 is less potent than LSD but is reported to have some LSD-like effects at doses ranging from 75 to 1,000μg orally and a shorter duration. It may only produce weak or threshold psychedelic effects in humans. There have been said to be fewer signs of cardiovascular stimulation and peripheral toxicity with LSM-775 compared to LSD. https://www.erowid.org/library/books_online/tihkal/tihkal26.shtml "LSM-775, N-Morpholinyllysergamide. There are conflicting reports; one states that 75 micrograms is an effective dose, comparable to a similar dose of LSD, and the other stated that between 350 and 700 micrograms was needed to elicit this response, and that there were fewer signs of cardiovascular stimulation and peripheral toxicity." On the other hand, more recent reports suggest that LSM-75 produces considerable nausea and feelings of lethargy and sedation.
Interactions
Pharmacology Pharmacodynamics LSM-775 is a potent full agonist of the serotonin 5-HT1A receptor and a potent partial agonist of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors. It does not produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. However, LSM-775 can robustly increase head twitches if it is coadministered with the serotonin 5-HT1A receptor antagonist WAY-100635. These findings indicate that serotonin 5-HT1A receptor activation suppresses the psychedelic-like effects of LSM-775.
Chemistry Synthesis The chemical synthesis of LSM-775 has been described.
Analogues Analogues of LSM-775 include the cyclized lysergic acid piperidide (LA-Pip), lysergic acid azepane (LA-Azepane), lysergic acid pyrrolidide (LA-Pyr; LPD-824), lysergic acid pyrrolinide (LPN), and lysergic acid 2,4-dimethylazetidide (LA-Az, LSZ) and the non-cyclized LEO, LA-MeO, ergometrine, and methylergometrine, among others.
History LSM-775 was first described in the scientific literature by Albert Hofmann and colleagues by 1955. It emerged as a novel designer drug in 2013.
Society and culture Legal status Canada LSM-775 is not a controlled substance in Canada as of 2025.
United States LSM-775 is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.
See also Substituted lysergamide Non-hallucinogenic 5-HT2A receptor agonist
References
External links LSM-775 - Isomer Design LSM-775 - PsychonautWiki LSD-25 (Discusses LSM-775) - TiHKAL - Erowid LSD-25 (Discusses LSM-775) - TiHKAL - Isomer Design The Big & Dandy LSM-775 (Lysergic Acid Morpholide) Thread - Bluelight